Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 1;33(3):137-146.
doi: 10.1097/ICU.0000000000000850. Epub 2022 Mar 9.

Complications of intravitreal injections: 2022

Dillan Patel  1 , Samir N Patel  2 , Varun Chaudhary  3   4 , Sunir J Garg  2
Affiliations
Review

Complications of intravitreal injections: 2022

Dillan Patel et al. Curr Opin Ophthalmol. .

Abstract

Purpose of review: This review highlights the complications of both intravitreal injection procedure as well as different intravitreal medications including antivascular endothelial growth factors, antibiotics, antivirals, antifungals, methotrexate, and steroids. Techniques for reducing rates of endophthalmitis will also be discussed.

Recent findings: Intravitreal vancomycin can cause hemorrhagic occlusive retinal vasculitis resulting in severe vision loss. Intravitreal brolucizumab is associated with intraocular inflammation and retinal vasculitis resulting in significant vision loss. Face mask use by both patient and physician is not associated with increased risk of endophthalmitis and may decrease culture positive endophthalmitis.

Summary: Intravitreal injections continue to be one of the most commonly performed procedures by ophthalmologists. Although the injections are generally well tolerated, sight-threatening complications can occur including endophthalmitis, retinal detachment, and/or retinal vasculitis. Adverse events associated with specific medications are outlined below. Several safety measures have been shown to reduce rates of endophthalmitis, the most concerning complication of this procedure.

PubMed Disclaimer

References

    1. Meyer CH, Krohne TU, Charbel Issa P, et al. Routes for drug delivery to the eye and retina: intravitreal injections. Dev Ophthalmol 2016; 55:63–70.
    1. McLaughlin MD, Hwang JC. Trends in vitreoretinal procedures for Medicare beneficiaries, 2000 to 2014. Ophthalmology 2017; 124:667–673.
    1. Pancholy M, Storey PP, Levin HJ, et al. Endophthalmitis following intravitreal anti-vascular endothelial growth factor therapy: changes in incidence and outcomes over a 9-year period. Curr Eye Res 2021; 46:1370–1377.
    1. Morioka M, Takamura Y, Nagai K, et al. Incidence of endophthalmitis after intravitreal injection of an anti-VEGF agent with or without topical antibiotics. Sci Rep 2020; 10:22122.
    1. Shrestha R, Karki P, Joshi SN. Outcome of intravitreal bevacizumab injection without pre and postoperative antibiotics. BMC Ophthalmol 2020; 20:145.